Pancreas-derived plasminogen activator inhibitor
    41.
    发明申请
    Pancreas-derived plasminogen activator inhibitor 审中-公开
    胰腺来源的纤溶酶原激活物抑制剂

    公开(公告)号:US20060045878A1

    公开(公告)日:2006-03-02

    申请号:US11048774

    申请日:2005-02-03

    摘要: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.

    摘要翻译: 本发明涉及纤溶酶原激活物抑制剂蛋白家族的新成员。 特别地,提供编码胰腺衍生的纤溶酶原激活物抑制蛋白的分离的核酸分子。 还提供了胰腺来源的纤溶酶原激活物抑制剂多肽,载体,宿主细胞和用于制备它们的重组方法。 本发明还涉及用于治疗生理和病理疾病状况的方法以及用于检测病理学疾病的诊断方法。

    T1 Receptor-Like Ligand II and Uses Thereof
    45.
    发明申请
    T1 Receptor-Like Ligand II and Uses Thereof 审中-公开
    T1受体样配体II及其用途

    公开(公告)号:US20070280903A1

    公开(公告)日:2007-12-06

    申请号:US11554432

    申请日:2006-10-30

    摘要: The present invention relates to a novel T1 Receptor (T1R)-like ligand II protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand II protein. T1R-like ligand II polypeptides are also provided, as are recombinant vectors and host cells for expressing the same. This invention further relates to pharmaceutical compositions and formulations comprising T1R-like ligand II. Also provided are methods of using T1R-like ligand II polynucleotides, polypeptides, antibodies or agonists/antagonists for therapeutic and diagnostic purposes. Diagnostic kits are further provided.

    摘要翻译: 本发明涉及一种新颖的T1受体(T1R)样配体II蛋白。 特别地,提供编码T1R样配体II蛋白质的分离的核酸分子。 还提供了T1R样配体II多肽,重组载体和用于表达它们的宿主细胞也是如此。 本发明还涉及包含T1R样配体II的药物组合物和制剂。 还提供了用于治疗和诊断目的的T1R样配体II多核苷酸,多肽,抗体或激动剂/拮抗剂的方法。 还提供诊断试剂盒。

    Novel Metalloproteinases
    46.
    发明申请
    Novel Metalloproteinases 审中-公开
    新型金属蛋白酶

    公开(公告)号:US20070238130A1

    公开(公告)日:2007-10-11

    申请号:US11627246

    申请日:2007-01-25

    摘要: The present invention relates to novel metalloproteinase- like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.

    摘要翻译: 本发明涉及新型金属蛋白酶样蛋白质。 特别地,提供了分离的核酸分子,其编码人类TACE样和基质溶素样蛋白。 TACE样和基质溶素样多肽也可以作为载体,宿主细胞和用于制备它们的重组方法提供。 本发明进一步涉及用于鉴定TACE样和基质溶素样活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测癌症的诊断方法和癌症的治疗方法以及特征在于这些金属蛋白酶过度或过量生产的其它病症。

    Leukocyte regulatory factors 1 and 2
    47.
    发明申请
    Leukocyte regulatory factors 1 and 2 审中-公开
    白细胞调节因子1和2

    公开(公告)号:US20060063924A1

    公开(公告)日:2006-03-23

    申请号:US11272833

    申请日:2005-11-15

    CPC分类号: C07K14/4702

    摘要: The present invention relates to novel LRF-1 and LRF-2 proteins which are related to the CRISP family and a protein called “Neutrophil Inhibitory Factor (NIF)” isolated from the canine hookworm (Ancylostoma caninum) that potently inhibits CD11/CD18-dependent neutrophil function. In particular, isolated nucleic acid molecules are provided encoding the human LRF-1 and LRF-2 proteins. LRF-1 and LRF-2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of LRF-1 or LRF-2 activity. Also provided are diagnostic methods for detecting immune system or other LRF-1- or LRF-2-related disorders and therapeutic methods for treating such disorders.

    摘要翻译: 本发明涉及与CRISP家族相关的新型LRF-1和LRF-2蛋白质,以及从犬钩虫(Ancylostoma caninum)中分离的称为“中性嗜中性粒细胞抑制因子(NIF)”的蛋白质,其有效抑制CD11 / CD18依赖性 中性粒细胞功能。 特别地,提供编码人LRF-1和LRF-2蛋白的分离的核酸分子。 还提供了LRF-1和LRF-2多肽,载体,宿主细胞以及用于制备它们的重组方法也是如此。 本发明还涉及用于鉴定LRF-1或LRF-2活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测免疫系统或其他LRF-1或LRF-2相关疾病的诊断方法以及用于治疗这种疾病的治疗方法。

    Nucleic acids encoding tumor necrosis factor receptor 5
    50.
    发明授权
    Nucleic acids encoding tumor necrosis factor receptor 5 失效
    编码肿瘤坏死因子受体5的核酸

    公开(公告)号:US06261801B1

    公开(公告)日:2001-07-17

    申请号:US09006353

    申请日:1998-01-13

    IPC分类号: C12P2102

    CPC分类号: C07K14/70578 A61K48/00

    摘要: The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as “TNFR-5” or “TR5”, and now referred to hereinafter as “TRAIL receptor without intracellular domain” or “TRID.” TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.

    摘要翻译: 本发明涉及编码作为TNF受体家族成员的多肽的新型人基因,现已发现其结合TRAIL。 更具体地,提供编码称为肿瘤坏死因子受体-5(有时称为“TNFR-5”或“TR5”)的人多肽的分离的核酸分子,以下在下文中称为“没有细胞内结构域的TRAIL受体”或 “TRID”。 还提供了TRID多肽,载体,宿主细胞以及用于制备它们的重组方法也是如此。 本发明还涉及用于鉴定TRAIL多肽活性的激动剂或拮抗剂的筛选方法。 还提供了利用这种组合物的诊断和治疗方法。